ASTERIAS BIOTHERAPEUTICS INC (AST) Stock News

AST SpaceMobile Stock Is Tumbling After Hours: What's Going On?

AST SpaceMobile Inc (NASDAQ: ASTS) shares are moving lower in extended trading Tuesday after the company announced a public offering of common stock.

Mentions: ASTS

Asterias Biotherapeutics Inc Class A to Host Earnings Call

The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Earnings and U.S. midterm polls continued to positively influence biotech stocks, with the sector notching gains for the second straight week. These are some of the upcoming...

Mentions: XBI ARWR CLDX CYCC ...

Wolf Popper LLP Investigates the Proposed Acquisition of Asterias Biotherapeutics, Inc. by BioTime, Inc.

BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company

Mentions: BTX

BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update

Mentions: BTX

Best & Worst Performing Small Cap Stocks for October 26, 2018 Premium

AST – AST leads the way today as the best performing small cap stock, closing up 46.25%.

H.C. Wainwright Sticks to Its Buy Rating for Asterias Biotherapeutics (AST)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $11. The company’s shares closed yesterday at $1.40, close to its 52-week low of $1.20. According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.7% and a 45.0% success rate.

Analysts Are Bullish on Top Healthcare Stocks: Asterias Biotherapeutics (AST), Cyclacel Pharmaceuticals (CYCC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Asterias Biotherapeutics (NYSE:AST) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) with bullish sentiments. Asterias Biotherapeutics (AST) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Asterias Biotherapeutics, with a price target of $11. The

Mentions: CYCC

Asterias Biotherapeutics, Inc. Common Series A (AST): Downgrade News

AST – Raymond James cuts to market perform. Stock price at the time of this analyst call was $1.55.

Asterias Biotherapeutics (AST) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $11. The company’s shares closed yesterday at $1.55, close to its 52-week low of $1.20. Selvaraju wrote: “Valuation methodology, risks and uncertainties. We use a sum-of-the-parts approach, which ascribes a $440M risk-adjusted net present

B.Riley FBR Maintains a Buy Rating on Asterias Biotherapeutics

B.Riley FBR analyst George Zavoico maintained a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $6. The company’s shares opened today at $1.75. Zavoico noted: “Asterias Biotherapeutics, Inc. (AST) announced additional interim results of its Phase I/IIa SCiStar trial of its AST-OPC1 cell therapy in patients with a severe

Asterias Biotherapeutics, Inc. Common Series A (AST): Product News News

AST – Company releases six-month data from its ongoing Phase 1/2a clinical trial, SCiStar, evaluating AST-OPC1 in patients with severe spinal cord injury.

H.C. Wainwright Sticks to Its Buy Rating for Asterias Biotherapeutics

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ...

The post H.C. Wainwright Sticks to Its Buy Rating for Asterias Biotherapeutics appeared first on Smarter Analyst.

Asterias Biotherapeutics Receives a New Rating from H.C. Wainwright

Asterias Biotherapeutics (NYSE: AST) received a Buy rating and a $11 price target from H.C. ...

The post Asterias Biotherapeutics Receives a New Rating from H.C. Wainwright appeared first on Smarter Analyst.

Asterias Biotherapeutics Receives a New Rating from H.C. Wainwright

Asterias Biotherapeutics (NYSE: AST) received a Buy rating and a $11 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed yesterday at $1.85. Selvaraju observed: “We reiterate our Buy rating and 12-month price target of $11 on AST.” According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of